Cagrilintide vs Retatrutide
Extensively Studied vs Extensively Studied
monitor Researched · 90% Compounded GI side effects create substantial risk without specialist supervision.
Molecular Data
Cagrilintide Retatrutide
Weight 4,409.01 Da 4,731.33 Da
Half-life ~7 days (159-195 hours) ~6 days
Chain 37 amino acids 39 amino acids
Type Amylin receptor agonist Triple GLP-1/GIP/glucagon agonist
Key Benefits
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
Cagrilintide Retatrutide
Status Extensively Studied Extensively Studied
References 3 studies 6 studies
Latest December 2025 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.